Discovery of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer

BTX-9341 - BioTheryX

Kisqali (ribociclib) - Novartis

Ibrance (palbociclib) - Pfizer

Verzenio (abemaciclib) - Eli Lilly

H. Majeski; A. Okano; K. Chahal; A. Pasis; C. Carlson; A. Shakya; Q. Liu; S. Huang; A. Hoskote Chourasia; L. Fung

Mar 6, 2024